GCS Ramsay Santé pour l'Enseignement et la Recherche

ramsaygds.fr

Live pipeline data from ClinicalTrials.gov, refreshed daily.

Total trials

233

Active

87

Phase 3

2

Total enrollment

94,024

Pipeline matrix

Showing 7 of 7 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
MORPHINE2
Lidocaine IV1
24 hours antibiotics1
48 hours antibiotics1
Intravenous lidocaine administration1
Neuroleptanalgesia1
Neuroleptanalgesic treatment1

Next readouts

  • 2026-01-18
  • 2026-05-31
  • 2026-11
  • 2027-07-30
  • 2027-08-31

Top conditions

  • ACL - Anterior Cruciate Ligament Rupture7
  • Prostate Cancer6
  • Latarjet4
  • Shoulder Injuries4
  • Endometriosis4
  • Analgesia4
  • Knee Injuries3
  • Gonarthrosis3

Frequently asked questions about GCS Ramsay Santé pour l'Enseignement et la Recherche

How many clinical trials does GCS Ramsay Santé pour l'Enseignement et la Recherche have on ClinicalTrials.gov?
GCS Ramsay Santé pour l'Enseignement et la Recherche is listed as the lead sponsor on 233 clinical trials in ClinicalTrials.gov, 87 of which are currently active (recruiting, enrolling, or ongoing).
How many of GCS Ramsay Santé pour l'Enseignement et la Recherche's trials are in Phase 3?
2 of GCS Ramsay Santé pour l'Enseignement et la Recherche's trials are in Phase 3, spread across 7 active drug programs.
What therapeutic areas does GCS Ramsay Santé pour l'Enseignement et la Recherche focus on?
GCS Ramsay Santé pour l'Enseignement et la Recherche's most-studied conditions on ClinicalTrials.gov are ACL - Anterior Cruciate Ligament Rupture, Prostate Cancer, Latarjet, Shoulder Injuries, Endometriosis.
When are GCS Ramsay Santé pour l'Enseignement et la Recherche's next clinical trial readouts?
GCS Ramsay Santé pour l'Enseignement et la Recherche has 5 upcoming primary-completion readouts tracked here; the soonest is “Evaluation of the Benefit of Lidocaine on the Prevention of the Risk of Post Endoscopic Retrograde Cholangio-pancreatography Pancreatitis.”, expected around 2026-01-18.